Loading
Life sciences · Journal article
Gastrointestinal Disorders · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, and many patients present with intermediate or advanced disease. Transarterial chemoembolization (TACE) is an established treatment; however, its proangiogenic effects support the use of combination therapy. Combinations of TACE with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have shown a promising antitumor activity. The objective of this study was to describe post-treatment mRECIST response patterns of TACE alone, TACE plus lenvatinib and pembrolizumab, and TACE plus atezolizumab and bevacizumab for HCC. Methods: This multicentre retrospective, non-randomized pilot study included 25 consecutive patients with unresectable HCC treated with TACE alone (n = 10), TACE–lenvatinib–pembrolizumab (n = 7), or TACE–atezolizumab–bevacizumab (n = 8). The primary outcome was first post-treatment mRECIST response. ORR and DCR were calculated descriptively. Secondary outcomes included imaging interval, TACE exposure, repeat TACE, ALBI change, and OS, estimated using Kaplan–Meier methods. Results: Complete response, partial response, stable disease, and progressive disease occurred in 30.0%, 30.0%, 10.0%, and 30.0% after TACE alone, 14.3%, 28.6%, 57.1%, and 0% after TACE–lenvatinib–pembrolizumab, and 0%, 37.5%, 0%, and 62.5% after TACE–atezolizumab–bevacizumab. ORR/DCR were 60.0%/70.0%, 42.9%/100.0%, and 37.5%/37.5%, respectively. Median imaging intervals were 38.0, 25.0, and 20.0 months. ALBI-grade worsening occurred in 30.0%, 42.9%, and 37.5%; 1-year OS was 78.8%, 83.3%, and 50.0%, respectively. Conclusions: mRECIST response patterns were heterogeneous. Baseline liver-function imbalance, small groups, and non-randomized allocation preclude comparative efficacy inference. Larger prospective studies should standardize treatment sequencing, imaging, liver function assessment, safety monitoring, and survival evaluation.